You are on Trendlyne United States. Click here to go to India website or make United States as your default
person reading

About Mineralys Therapeutics Inc - Company Information, Overview, History and Profile

What does Mineralys Therapeutics Inc do?

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics Inc Management structure

All Gross Remunerations are in USD
Mr. Adam S. Levy
Chief Financial Officer, Principal Accounting Officer and Secretary
-
2024
Gross Remuneration
Year
Mr. Jon Congleton
Chief Executive Officer and Director
-
2024
Gross Remuneration
Year
Dr. David Rodman, M.D.
Chief Medical Officer
-
2024
Gross Remuneration
Year

Mineralys Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Dr. Alexander G. Asam, PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Olivier Litzka, PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Alexander M. Gold, M.D.
Independent Director
-
2024
Gross Remuneration
Year
Mr. Glenn P. Sblendorio
Independent Director
-
2024
Gross Remuneration
Year
Dr. Srinivas Akkaraju, M.D.,PhD
Independent Director
-
2024
Gross Remuneration
Year
Mr. Jon Congleton
Chief Executive Officer and Director
-
2024
Gross Remuneration
Year